AAD: Promising Results Seen for Bimekizumab in Hidradenitis Suppurativa
Significantly higher proportion of hidradenitis suppurativa patients treated with bimekizumab achieved primary end point of HiSCR50
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.